Text Size
Trial record 9 of 176 for:    "Essential thrombocythemia"
Previous Study | Return to List | Next Study

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

This study is currently recruiting participants.
Verified March 2013 by NS Pharma, Inc.
Sponsor:
Information provided by (Responsible Party):
NS Pharma, Inc.
ClinicalTrials.gov Identifier:
NCT01423851
First received: August 15, 2011
Last updated: March 21, 2013
Last verified: March 2013
History of Changes
  Purpose

The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (post-ET MF)


Condition Intervention Phase
Primary Myelofibrosis
Post-Polycythemic Vera Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis
 Drug: NS-018
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by NS Pharma, Inc.:

Primary Outcome Measures:
  • To evaluate safety and tolerability of NS-018 assessed by the type, frequency, seriousness and intensity of adverse events [ Time Frame: Throughout the study until 30 days after the last dose of study drug (patients with disease progression or no clinical benefit after 6 cycles [168 days] will be discontinued from the study) ] [ Designated as safety issue: Yes ]
    Phase 1 and Phase 2

  • To establish maximum tolerated dose of NS-018 [ Time Frame: Cycle 1 (28 days) ] [ Designated as safety issue: Yes ]
    Phase 1

  • To evaluate response to NS-018 treatment using the International Working Group (IWG) consensus criteria, change in spleen size and bone marrow assessment [ Time Frame: Day 29, 57, 85, and every 84 days thereafter ] [ Designated as safety issue: No ]
    Phase 2


Secondary Outcome Measures:
  • To determine the pharmacokinetic parameters of NS-018 (Cmax, Tmax, AUC, t1/2 and accumulation ratio) [ Time Frame: Up to 24 hours post-dose on Day 1, 8, 15, 29 ] [ Designated as safety issue: No ]
    Phase 1 and Phase 2

  • To evaluate pharmacodynamic correlates of NS-018 [ Time Frame: Day 1, 8, 15, 29, 57, 85, and every 84 days thereafter ] [ Designated as safety issue: No ]
    Phase 1 and Phase 2

  • To evaluate quality of life assessments using Myelofibrosis Symptom Assessment Form (MF-SAF) [ Time Frame: Day 29, 85, and every 84 days thereafter ] [ Designated as safety issue: No ]
    Phase 1 and Phase 2


Estimated Enrollment: 44
Study Start Date: June 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intervention: Drug: NS-018 Drug: NS-018
Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Primary myelofibrosis, post-PV MF, or post-ET MF that requires therapy
  • ≥18 years old
  • ECOG Performance Status of ≤2
  • Estimated life expectancy of ≥12 weeks
  • Male or non-pregnant, non-lactating female patients
  • Serum creatinine of ≤1.5 × the upper limit of normal (ULN)OR estimated creatinine clearance (CrCl) ≥60 ml/min/1.73 m2
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × the upper limit of normal (ULN) and total bilirubin ≤1.5 × ULN
  • Absolute neutrophil count (ANC) >1000/μL and Platelet count >50,000/μL
  • QTcB ≤480 msec
  • No MF-directed treatment for at least 2 weeks prior to initiation of NS-018

Exclusion Criteria:

  • Active, uncontrolled systemic infection
  • Patients with any unresolved toxicity greater than Grade 1 from previous anticancer therapy
  • Potentially curative therapy is available
  • Currently taking medication that is substantially metabolized by cytochrome P450 (CYP) 1A2 or CYP3A4 or taking medication known to be strong inhibitors or inducers of CYP3A4
  • Patients with a serious cardiac condition within the past 6 months
  • Pregnant or lactating
  • Radiation therapy for splenomegaly within 6 months prior to study entry
  • Splenectomy (Phase 2 portion of the study only)
  • Known HIV positive status
  • Known active hepatitis, a history of viral hepatitis B or hepatitis C, or known positive hepatitis B serologies without a history of immunization
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01423851

Locations
United States, Arizona
Mayo Clinic Scottsdale Recruiting Recruiting
Scottsdale, Arizona, United States, 85259-5499
Contact: Clinical Trials Office - All Mayo Clinic Locations     507-538-7623        
Principal Investigator: Ruben A. Mesa, M.D.            
United States, California
UC San Diego Moores Cancer Center Not yet recruiting
San Diego, California, United States, 92093-0698
Principal Investigator: Catriona Jamieson, MD, PhD            
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Hala Simm     312-695-7559        
Principal Investigator: Brady Stein, MD            
University of Chicago Not yet recruiting
Chicago, Illinois, United States, 60637
Contact: Lisa Pape     773-702-6206     lpape@medicine.bsd.uchicago.edu    
Contact: Peggy Green     773-7702-0267     mgreen@medicine.bsd.uchicago.edu    
Principal Investigator: Olatoyosi Odenike, MD            
United States, Massachusetts
Dana Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02115
Principal Investigator: Martha Wadleigh, MD            
United States, Michigan
University of Michigan Not yet recruiting
Ann Arbor, Michigan, United States, 48109
Principal Investigator: Moshe Talpaz, MD            
United States, New York
Weill Cornell Medical College Not yet recruiting
New York, New York, United States, 10021
Principal Investigator: Ellen Ritchie, MD            
United States, Texas
MD Anderson Cancer Center, Department of Leukemia Recruiting
Houston, Texas, United States, 77030
Contact: Srdan Verstovsek, M.D., Ph.D.     713-745-3429     sverstov@mdanderson.org    
Principal Investigator: Srdan Verstovsek, M.D., Ph.D.            
Sponsors and Collaborators
NS Pharma, Inc.
Investigators
Principal Investigator: Srdan Verstovsek, M.D., Ph.D. MD Anderson Cancer Center, Houston, TX, 77030
  More Information

No publications provided

Responsible Party: NS Pharma, Inc.
ClinicalTrials.gov Identifier: NCT01423851     History of Changes
Other Study ID Numbers: NS-018-101
Study First Received: August 15, 2011
Last Updated: March 21, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by NS Pharma, Inc.:
post-Essential Thrombocythemia Myelofibrosis
Keywords provided by NS Pharma, Inc.:
JAK2 kinase inhibitor
NS-018
Myeloproliferative Neoplasms
Primary Myelofibrosis
post-Polycythemia Vera Myelofibrosis
Additional relevant MeSH terms:
 Bone Marrow Diseases
Hematologic Diseases
Polycythemia Vera
Thrombocythemia, Essential
PMF
post-PV MF
post-ET MF

Additional relevant MeSH terms:
Primary Myelofibrosis
Polycythemia
Polycythemia Vera
Thrombocythemia, Essential
Thrombocytosis
Myeloproliferative Disorders
 Bone Marrow Diseases
Hematologic Diseases
Blood Coagulation Disorders
Blood Platelet Disorders
Hemorrhagic Disorders

ClinicalTrials.gov processed this record on May 23, 2013